Veeda Clinical Research Unlisted Shares
Veeda Clinical Research Refiles IPO Documents With SEBI
The Pinnacle Gazette
2 min read
Veeda Clinical Research Refiles ₹185 Crore IPO.
Expert Analysis:
IPO Refiled: Veeda Clinical Research refiles its DRHP with SEBI for its IPO with a ₹2 face value shares,₹185 crore fresh issue, and 13 million shares for sale, initially submitted on September 27, 2021.
Strong Financial Growth: Veeda's revenue grew at a 16.18% CAGR (FY22-FY24), with TAM projected to expand from USD 65.4B to USD 110.7B by 2028.
Revenue & Client Growth: Veeda reported ₹305.30 crore revenue (H1 FY25) with 436 active clients, completing 580 studies in FY22, showcasing global market strength.
Fund Allocation: Funds to be used for ₹50 crore for equipment, ₹35 crore for Bioneeds' capital expenditure, and ₹10.89 crore for Bioneeds' debt repayment to drive growth.
Organic Growth Focus: ₹33 crore allocated for marketing, tech upgrades, and digital modernization to enhance efficiency and quality assurance.
Regulatory Strength & IPO Management: 119 successful global inspections highlight Veeda’s compliance, with Axis Capital, CLSA, IIFL, and SBI Capital managing the IPO.
Strategic Positioning: Veeda’s IPO aims to fund growth, strengthen its clinical research portfolio, and advance global healthcare R&D efforts.
Veeda’s IPO supports R&D, tech upgrades, and growth in the ₹9.65 trillion clinical research industry.
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved